Recently, a number of novel quinolones with potent activity against topoisomerase H and eukaryotic cells have been described. Many of these compounds contain aromatic substituents in their C-7 ring positions. To determine whether pyrimido[1,6-albenzimidazoles, a class of drugs modeled on quinolones, also display activity toward eukaryotic systems, the effects of Ro 46-7864 and Ro 47-3359 on Drosophila melanogaster topoisomerase II and Kc cells were characterized. While the former drug contains an aliphatic group (4-N-methylpiperazine) at the ring position equivalent to C-7 in quinolones, the latter compound contains an aromatic substituent (2,6-dimethylpyridine). Both pyrimido [1,6- 
at the ring position equivalent to C-7 in quinolones, the latter compound contains an aromatic substituent (2,6-dimethylpyridine) . Both pyrimido [1,6-albenzimidazoles Quinolone-based drugs are some of the most active and widely used antimicrobial agents (4, 11, 30) . The primary cellular target for these clinically important drugs is the prokaryotic type II topoisomerase, DNA gyrase (4, 11, 27, 30, 36) . Quinolones alter the normal catalytic activity of DNA gyrase in a manner that converts this essential enzyme into a potent physiological poison (22) . They act by stabilizing covalent gyrase-cleaved DNA complexes that are normal intermediates in the catalytic cycle of the enzyme (9, 36, 45) . Hence, treatment of bacteria with quinolones induces protein-associated breaks in the genetic material, triggers the SOS response, and eventually leads to cell death (4, 22, 27, 35) .
Antimicrobial quinolones that are used clinically for the treatment of bacterial infections have little activity against eukaryotic topoisomerase II (2, 5, 10, 12, 13, 17, 28, 29, 31, 33) . However, a number of novel quinolones that have potent activity against the eukaryotic type II enzyme have recently been identified (2, 5-7, 19-21, 37, 38, 46, 48-50) . Many of these compounds enhance topoisomerase II-mediated DNA breakage and are cytotoxic to cultured cells, solid tumors, or both (2, 5-7, 19-21, 37, 38, 46, 48-50) . It is not entirely clear how alterations in quinolone ring substituents transform these gyrase-targeted antimicrobial agents into drugs that target the eukaryotic enzyme. It is notable, however, that many of the compounds that show high levels of activity against topoisomerase II have an aromatic substituent at the C-7 ring position (2, 5-7, 19, 20, 37, 38, 48, 49) , while clinically relevant antimicrobial quinolones all contain an aliphatic substituent at this position (see Fig. 1 ) (3, 47) .
Because of the clinical importance of quinolones, compounds related to these drugs have been assessed for their activities against DNA gyrase (3, 16) . One such class of compounds that was modeled on the quinolones is the * Corresponding author.
pyrimido [1,6-a] benzimidazoles (16) . Members of this drug class display activity against the bacterial type II enzyme that is similar to that of clinically relevant quinolone antibiotics such as norfloxacin and fieroxacin (16) .
Considering the antineoplastic potential of quinolones targeted to topoisomerase II, it is worthwhile to determine whether compounds with related structures also display activity against eukaryotic systems. Therefore, the effects of two novel pyrimido [1,6-a] benzimidazoles, Ro 46-7864 and Ro 47-3359 (see Fig. 1 ), on Drosophila melanogaster topoisomerase II and embryonic tissue culture cells were characterized. While the former drug contains an aliphatic substituent (4-N-methylpiperazine) in the ring position equivalent to C-7 in quinolones, the latter drug contains an aromatic substituent (2,6-dimethylpyridine). Although both pyrimido [1,6-a] benzimidazoles inhibited the DNA relaxation activity of D. melanogaster topoisomerase II, only Ro 47-3359 enhanced enzyme-mediated DNA cleavage and was toxic to cultured cells. These results indicate that pyrimido [1,6a] benzimidazoles represent a novel class of topoisomerase II-targeted drugs with cytotoxic potential and suggest that the drug features at the C-7 position that promote the activities of these compounds toward eukaryotic systems may be similar to those described previously (2, 5-7, 19, 20, 37, 38, 48, 49) for quinolones.
MATERIALS AND METHODS
Chemicals. DNA topoisomerase II was purified from the nuclei of 6-to 12-h-old D. melanogaster embryos as described by Shelton et al. (44) . Negatively supercoiled pBR322 plasmid DNA was isolated from Escherichia coli DH1 by a Triton X-100 lysis procedure followed by double banding in cesium chloride-ethidium bromide gradients (41 Assays were carried out over a concentration range of 0 to 500 ,M drug. All control reactions contained the appropriate amount of drug diluent (DMSO).
Topoisomerase H-mediated DNA religation. Religation reactions were carried out as described previously (40) . Initial DNA cleavage-religation equilibria were established as described in the preceding section in the presence or absence of drug. Samples were then shifted to 55°C to initiate DNA religation. Reactions were stopped by the addition of SDS and EDTA, topoisomerase II was digested with proteinase K, and DNA products were analyzed as described above. The apparent first-order rate of religation was determined by quantitating the loss of the linear DNA band. Control reactions contained the appropriate amount of DMSO.
Topoisomerase If-mediated DNA relaxation. DNA relaxation assays were carried out by the protocol of Osheroff et al. (33) . Reaction mixtures contained 0.3 nM topoisomerase II, 5 nM negatively supercoiled pBR322 DNA, and 1 mM ATP in 20 ,u of assay buffer. Samples were incubated at 30°C for 15 min, and the incubation was stopped by the addition of 2.5 ,u of 0.77% SDS-77 mM EDTA. Two microliters of sample dye was added, and the products were resolved by agarose gel electrophoresis in 1% gels in 100 mM Tris-borate (pH 8.3)-2 mM EDTA. Following electrophoresis, gels were stained for 30 min in a 1-,g/ml solution of ethidium bromide.
The DNA bands were visualized as described above. The initial velocity of relaxation was determined by quantitating the loss of the supercoiled DNA band.
DNA intercalation. A topoisomerase I unwinding assay was used to monitor the intercalation of drugs into plasmid DNA (37) . Reactions were carried out in the presence or absence of 500 ,M drug in 20 ,ul of assay buffer that contained 5 nM relaxed pBR322 plasmid DNA and 10 U of topoisomerase I. Following a 15-min incubation at 37°C, samples were extracted with phenol-chloroform and were subjected to agarose gel electrophoresis, as described above, in Tris-acetate buffer. DNA bands were visualized by staining in ethidium bromide and were photographed as described in the previous sections.
Cytotoxicities of pyrimido [1,6- 
RESULTS
Gyrase-targeted quinolone antibiotics all contain aliphatic substituents at the C-7 ring position (3, 47 ). An example is fleroxacin, which contains a 4-N-methylpiperazine group at this position (see Fig. 1 ). Conversely, quinolones that display activity toward the eukaryotic type II enzyme often contain aromatic substituents at C-7 including hydroxyphenyl (5, 6, 37, 38) , quinoline (7), pyridine (2), and 2,6-dimethylpyridine (20, 48, 49) .
A recent study demonstrated that pyrimido[1,6-a]benzimidazoles have potential as gyrase-targeted antimicrobial agents (16) . As with the antibacterial quinolones, all of the compounds examined for antigyrase activity contained aliphatic substituents at the ring position equivalent to C-7. To determine whether members of the pyrimido[1,6-a]benzimidazole drug class also display activity against eukaryotic determined. As seen in Fig. 2 , Ro 46-7864 displayed virtually no ability to enhance the DNA cleavage activity of D. melanogaster topoisomerase II. As a control, the quinolone fleroxacin, which contains the same 4-N-methylpiperazine group found in Ro 46-7864 was examined. As expected, this antibiotic did not stimulate (and, in fact, slightly decreased) enzyme-mediated DNA scission. In marked contrast, Ro 47-3359, which contains an aromatic substituent in place of the 4-N-methylpiperazine, enhanced the cleavage activity of topoisomerase II. Levels of double-stranded DNA breaks increased twofold at -100 ,uM drug and tripled at a concentration of -500 ,uM Ro 47-3359 ( Fig. 2; Two control experiments were carried out to demonstrate that the effects of Ro 47-3359 on DNA cleavage are mediated solely by topoisomerase II (Fig. 3) . First, DNA was incubated with 500 ,uM drug in the absence of the enzyme. Ro 47-3359 alone produced no nucleic acid cleavage (lane 5). Second, when DNA cleavage products were not treated with proteinase K, all of the linear plasmids (i.e., molecules with double-stranded breaks) generated during the assay were covalently bound to topoisomerase II and migrated with an altered electrophoretic mobility (lane 4). In order to release the cleaved DNA, the enzyme had to be digested with proteinase K (lane 3). This covalent linkage of the enzyme to cleaved nucleic acids is a hallmark of the topoisomerase II-mediated DNA cleavage reaction (26, 34, 42 (37, 38) . The effect of Ro 47-3359 on topoisomerase II-mediated DNA religation was determined by a heat reversal assay (14, 15, 40) . As seen in Fig. 4 , the apparent first-order rate of DNA religation observed in the presence of 500 ,uM Ro VOL. 37, 1993 Inhibition of topoisomerase H-catalyzed DNA relaxation by pyrimido[1,6-albenzimidazoles. Most drugs that alter the DNA cleavage-religation equilibrium of topoisomerase II also affect overall catalytic activity (23, 24) . Therefore, in order to assess the effects of pyrimido [1,6- a]benzimidazoles on the catalytic activity of topoisomerase II, the abilities of Ro 46-7864 and Ro 47-3359 to inhibit enzyme-catalyzed DNA relaxation were investigated.
In contrast to their differential effects on DNA cleavage, both drugs inhibited the overall catalytic activity of topoisomerase II to a similar extent (Fig. 5) . Two possible explanations for this inhibition exist. First, these drugs may intercalate into DNA and inhibit relaxation of the supercoiled plasmid by altering the apparent topological state of the nucleic acid substrate. Second, these drugs may interact directly with the enzyme or the enzyme-DNA complex and inhibit activity by interfering with one or more steps of the topoisomerase II catalytic cycle. In order to distinguish between these two possibilities, a DNA intercalation assay was performed (Fig. 6) . In this assay, relaxed plasmid DNA was incubated with topoisomerase I and 500 ,uM drug. In the presence of intercalative drugs such as amsacrine, a net negative supercoiling of the relaxed DNA substrate was induced (lane 3). Conversely, in the presence of nonintercalative drugs such as etoposide, no change in the topological state of the relaxed plasmid was observed (lane 4). shown over a range of 0 to 500 ,uM drug. Data are the averages of two independent experiments. The standard error in the data was less than 7%. Levels of enzyme activity were set to 100% in the absence of drug.
As determined by the slight shift in the superhelicity of the plasmid substrate, both pyrimido[1,6-a]benzimidazoles intercalated weakly into the DNA (lanes 5 and 6). Form I pBR322 plasmid DNA contains about 25 negatively supercoiled twists (as isolated from E. coli) (25, 40) . At a concentration of 500 ,uM, Ro 47-3359 and Ro 46-7864 unwound approximately three and six superhelical twists, respectively. Since the two drugs inhibited DNA relaxation by 50% at a concentration of <250 ,uM, the levels of intercalation observed are not sufficient to account for the effects of these compounds on the DNA relaxation activity of topoisomerase II. Therefore, it is likely that pyrimido [1,6- As previously demonstrated for the quinolones (37, 38), Ro 47-3359 enhances topoisomerase II-mediated DNA breakage without impairing the ability of the enzyme to religate cleaved DNA. Furthermore, as found for quinolonebased drugs (5, 7, 38) , the cytotoxicities of pyrimido [1,6-a] benzimidazoles correlated with their enhancement of DNA cleavage rather than with their inhibition of overall topoisomerase II catalytic function. Therefore, in addition to their structural similarities, there appear to be mechanistic parallels between these two drug classes.
While all clinically relevant antibacterial quinolones contain aliphatic substituents at ring position C-7 (3, 47), many quinolones that display antineoplastic potential have aromatic substituents at this ring position (2, 5-7, 19, 20, 37, 38, 48, 49) . The fact that Ro 47-3359, which has a 2,6-dimethylpyridine group in this position, enhanced DNA cleavage and killed cultured cells suggests that the structure-activity relationships that govern quinolone activity against eukaryotic systems also may apply to the pyrimido[1,6-a]benzimidazoles. This suggestion is supported by modeling studies that demonstrate that the spatial location and orientation of the C-7 substituent in quinolones are nearly identical to those of the equivalent substituent in pyrimido[1,6-a]benzimidazoles (16) .
Recent studies (2, 5-7, 19, 20, 21, 37, 38, 46, 48-50) indicate that quinolones, which in the past have been used exclusively as gyrase-targeted antimicrobial agents (4, 11, 30) , may someday play a role in the treatment of human cancers. Results of the present work demonstrate that selected pyrimido [1,6-a] benzimidazoles, like the quinolones, are active against eukaryotic systems. Thus, pyrimido [1,6-a] benzimidazoles represent the second class of gyrase inhibitors that also contains novel compounds with antineoplastic potential.
